How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Real World Evidence Solutions(RWE) for Oncology Market
- By Solution Type: Data Collection and Integration Platforms, Data Analytics and Visualization Tools, Clinical Trial Optimization Solutions, Regulatory Compliance and Reporting Tools, Patient Journey Mapping Solutions
- By Data Source: Electronic Health Records (EHR), Claims and Billing Data, Patient-Reported Outcomes (PRO), Genomic and Molecular Data, Imaging Data, Wearable and Sensor Data
- By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Healthcare Providers and Hospitals, Regulatory Authorities, Payers and Insurance Companies
- By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Hematologic Malignancies, Melanoma
- By Service Model: On-Premise Deployment, Cloud-Based Solutions, Hybrid Deployment
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Data Collection and Integration Platforms leads By Solution Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 306 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.185 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.193 →
Full report · locked preview
Everything inside the Real World Evidence Solutions(RWE) for Oncology Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Solution Type 5
Data Source 6
End User 5
Cancer Type 6
Service Model 3
Companies profiled
IQVIA
Flatiron Health (a subsidiary of Roche)
Syneos Health
Parexel International
ICON plc
Covance (Labcorp Drug Development)
Medidata Solutions (a Dassault Systèmes company)
COTA Inc.
Tempus Labs Inc.
Real World Data (RWD) Solutions by Evidera (PAREXEL)
HealthVerity
TriNetX
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →IQVIA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Flatiron Health (a subsidiary of Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Syneos Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Parexel International
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Covance (Labcorp Drug Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Medidata Solutions (a Dassault Systèmes company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →COTA Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Tempus Labs Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Real World Data (RWD) Solutions by Evidera (PAREXEL)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →HealthVerity
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →TriNetX
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Clarify Health Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →SAS Institute
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Pharmerit International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,893M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Data Collection and Integration Platforms31.7
- Data Analytics and Visualization Tools19.1
- Clinical Trial Optimization Solutions14.3
- Regulatory Compliance and Reporting Tools15.5
- Patient Journey Mapping Solutions19.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$371.0M → $599.1M · 6.2%
Europe$258.6M → $482.4M · 8.1%
Asia Pacific$236.1M → $372.2M · 5.9%
Latin America$146.1M → $247.9M · 6.8%
Middle East and Africa$112.4M → $171.0M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.682026
6.702027
6.722028
6.732029
6.742030
6.742031
6.762032
6.772033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- IQVIA13.7
- Flatiron Health (a subsidiary of Roche)23.4
- Syneos Health9.2
- Parexel International11.6
- ICON plc8.2
- Covance (Labcorp Drug Development)5.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Solution Type35.7%
Data Source12.8%
End User15.7%
Cancer Type18.3%
Service Model17.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe25.8
- Asia Pacific19.9
- Latin America13.2
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| IQVIA | 88 | 81 | 74 | 92 | 91 | 85 | 85 |
| Flatiron Health (a subsidiary of Roche) | 71 | 89 | 70 | 85 | 71 | 73 | 77 |
| Syneos Health | 83 | 87 | 80 | 68 | 76 | 69 | 77 |
| Parexel International | 65 | 67 | 71 | 58 | 78 | 78 | 70 |
| ICON plc | 71 | 56 | 75 | 75 | 66 | 59 | 67 |
| Covance (Labcorp Drug Development) | 68 | 60 | 50 | 69 | 48 | 66 | 60 |
| Medidata Solutions (a Dassault Systèmes company) | 49 | 42 | 63 | 65 | 60 | 64 | 57 |
| COTA Inc. | 36 | 41 | 54 | 46 | 40 | 44 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- IQVIA
- Flatiron Health (a subsidiary of Roche)
- Syneos Health
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| IQVIA | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Flatiron Health (a subsidiary of Roche) | ◐ | ◐ | ◐ | ✓ | − | ◐ |
| Syneos Health | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Parexel International | − | ✓ | ✓ | − | ✓ | ✓ |
| ICON plc | ◐ | ◐ | ◐ | ✓ | − | ◐ |
| Covance (Labcorp Drug Development) | ◐ | − | ◐ | − | − | − |
| Medidata Solutions (a Dassault Systèmes company) | ◐ | − | − | ✓ | ◐ | − |
| COTA Inc. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1IQVIA85
2Flatiron Health (a subsidiary of Roche)77
3Syneos Health77
4Parexel International70
5ICON plc67
6Covance (Labcorp Drug Development)60
7Medidata Solutions (a Dassault Systèmes company)57
8COTA Inc.44
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
IQVIA
Challenger4
Strong scale, closing on the leaders.
Flatiron Health (a subsidiary of Roche)Syneos HealthParexel InternationalICON plc
Contender2
Focused players with pockets of strength.
Covance (Labcorp Drug Development)Medidata Solutions (a Dassault Systèmes company)
Niche1
Specialists in a single segment or region.
COTA Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Solution Type in North America, then scale across Real World Evidence Solutions(RWE) for Oncology Market — a $347M beachhead inside a $6.69B market.
Beachhead (SOM)$347Mobtainable near-term
Serviceable (SAM)$2.37Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Data Collection and Integration Platforms
Best fit — highest urgency & budget in Solution Type.
Economic buyer76 fit
Data Analytics and Visualization Tools
Strong fit — clear ROI and a fast path to value.
End user70 fit
Clinical Trial Optimization Solutions
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Solution Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Data Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Solution Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Real World Evidence Solutions(RWE) for Oncology Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation14%
Closed-won5%
$22.0KCAC
$87KLTV
4.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Real World Evidence Solutions(RWE) for Oncology Market is a durable-growth opportunity — $7.83B by 2033, compounding at 6.2%.
TAM · 2025$4.85Btoday
TAM · 2033$7.83Bforecast
CAGR6.2%2027–2033
Cumulative$56.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.83BTotal addressable market
SAM$2.85BServiceable available market
SOM$474MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.2% CAGR
Demand compounds through 2033, outpacing GDP across Solution Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Solution Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.83BLarge & growingTAM by 2033 at 6.2% CAGR
$2.85BServiceable nowreachable with today’s model
$474MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.11BBear4.0% CAGR
$7.83BBase6.2% CAGR
$10.0BBull8.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Data Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Real World Evidence Solutions(RWE) for Oncology Market — a $6.73B market by 2033. Plan: grow share from 7.3% to 12.3%.
Market size · 2033$6.73Btotal addressable
Market CAGR11.2%2027–2033
Target share12.3%from 7.3% today
Revenue ambition$828Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 12.3% | Behind |
| Revenue | $525M | $828M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.9% | 41.3% | Ahead |
| Customer retention | 88.8% | 93.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Solution Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Data Source capability
A defensible second engine — invest in Data Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Solution Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Data Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $122M capacity & capability investment
- Greenlight bolt-on M&A in Data Source
- Authorise North America expansion plan
- Fund R&D program for Solution Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Real World Evidence Solutions(RWE) for Oncology Market conversation — a $3.54B market you can size, segment and defend in minutes.
Market size · 2033$3.54Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers1,462+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Solution Type
Goal Grow share in Solution Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 2 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
IQVIAFlatiron Health (a subsidiary of Roche)Syneos HealthParexel InternationalICON plcCovance (Labcorp Drug Development)Medidata Solutions (a Dassault Systèmes company)COTA Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Real World Evidence Solutions(RWE) for Oncology Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Real World Evidence Solutions(RWE) for Oncology Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Real-World Evidence Solution Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportReal-World Evidence in Healthcare Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportReal Time X-Ray System Market
Market size, share, segmentation and regional forecast.
$916M market · 2025 base year
View reportReal-time Virtual Sonography (RVS) Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportReal Time Viable Particle Counter Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportReal-time Tracking for Medical Packages Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportReal-Time Terahertz Spectrometers Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportReal-time RT-PCR Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportReal Time Radiography (RTR) Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportReal-time Radiography Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportReal-time PCR (RT-PCR) Fluorescence Probe Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportReal-Time PCR Reagents & Kits Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.